Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
Condition(s) studied
Investigational drug(s) / intervention(s)
Adjuvant chemoradiotherapy: Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)
Adjuvant chemotherapy: Chemotherapy (gemcitabine plus capecitabine)
Study summary
In this trial, we aim to compare the outcomes of adjuvant chemoradiotherapy with chemotherapy for patients with resected pancreatic cancer who are at high risk of disease progressions.
Eligibility
Primary outcome measure(s)
- Disease progression free survival will be determined. — 3 years
The time from the start of treatment until documentation of any clinical or radiological disease progression or death, whichever occurred first. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Huojun Zhang | Shanghai | Shanghai Municipality | Recruiting |
More Changhai Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06427447 on ClinicalTrials.gov ↗ ← All trials in China